Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 263.50M | 250.43M | 241.53M | 212.68M | 164.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 263.50M | 250.43M | 241.53M | 212.68M | 164.07M |
| Cost of Revenue | 187.99M | 182.67M | 175.71M | 150.42M | 107.94M |
| Gross Profit | 75.51M | 67.75M | 65.81M | 62.26M | 56.13M |
| SG&A Expenses | 152.58M | 158.50M | 163.28M | 165.15M | 152.62M |
| Depreciation & Amortization | 18.52M | 18.16M | 18.88M | 18.88M | 18.88M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 661.72M | 661.75M | 652.16M | 611.46M | 559.35M |
| Operating Income | -398.21M | -411.33M | -410.64M | -398.78M | -395.28M |
| Income Before Tax | -393.05M | -398.33M | -389.73M | -378.62M | -375.01M |
| Income Tax Expenses | -2.07M | -697.00K | 188.00K | -3.26M | -2.83M |
| Earnings from Continuing Operations | -390.98 | -397.63 | -389.92 | -375.36 | -372.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -390.98M | -397.63M | -389.92M | -375.36M | -372.18M |
| EBIT | -398.21M | -411.33M | -410.64M | -398.78M | -395.28M |
| EBITDA | -362.27M | -371.32M | -371.83M | -360.56M | -357.64M |
| EPS Basic | -1.12 | -1.20 | -1.23 | -1.23 | -1.30 |
| Normalized Basic EPS | -0.69 | -0.74 | -0.77 | -0.78 | -0.82 |
| EPS Diluted | -1.12 | -1.20 | -1.23 | -1.23 | -1.30 |
| Normalized Diluted EPS | -0.69 | -0.74 | -0.77 | -0.78 | -0.82 |
| Average Basic Shares Outstanding | 1.43B | 1.33B | 1.27B | 1.22B | 1.16B |
| Average Diluted Shares Outstanding | 1.43B | 1.33B | 1.27B | 1.22B | 1.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |